Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome

BACKGROUND: Patients with autoimmune diseases were not evaluated in clinical trials with immune checkpoint inhibitors (ICIs), since a history of immune disorders, such as Guillain–Barré syndrome (GBS) and psoriasis, is one of the major risk factors for the development of immune-related adverse event...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Case Rep Oncol Med
Main Authors: Cortellini, Alessio, Parisi, Alessandro, Fargnoli, Maria Concetta, Cannita, Katia, Irelli, Azzurra, Porzio, Giampiero, Martinazzo, Claudio, Ficorella, Corrado
פורמט: Artigo
שפה:Inglês
יצא לאור: Hindawi 2018
נושאים:
Case Report
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5863341/
https://ncbi.nlm.nih.gov/pubmed/29707397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/2783917
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים